Vaccines and Antibodies for Tomorrow's Threats
Building Preparedness & Collaboration
Our proactive collaborative research network aims to develop generalizable strategies for safe and effective vaccines and monoclonal antibodies to combat high-priority pathogens most likely to threaten human health.
THE NEED FOR RESEARCH COLLABORATION
Lessons from Past Outbreaks
In the wake of COVID-19 and other viral outbreaks such as SARS, Ebola, Zika, Dengue, and mPox, the National Institutes of Health (NIH) established a network to conduct research on high-priority pathogens most likely to threaten human health with the goal of developing effective vaccines and monoclonal antibodies. Currently, many of the diseases caused by these pathogens have no available vaccines or therapeutics, and investing in this research is key to preparing for potential public health crises—both in the United States and around the world.
The ReVAMPP Network will enable researchers to fill key knowledge gaps and identify strategies to develop safe and effective medical countermeasures for targeted virus families before the need becomes critical.
THE ReVAMPP NETWORK
Research and Development of Vaccines and
Monoclonal Antibodies
What Is the ReVAMPP Network?
What Is the ReVAMPP Network?
ReVAMPP is a research network designed to conduct fundamental basic to IND-enabling translational research on representative viruses, or “prototype pathogens,” within specific virus families. The Network consists of 7 multi-project Research Centers based at US research institutions, and a central Coordination and Data Sharing Center.
What is the ReVAMPP Approach & Goal?
What is the ReVAMPP Approach & Goal?
By leveraging a “prototype pathogen” approach, ReVAMPP will lay the groundwork for a faster and more effective public health response (vaccines and antibody therapies) should a virus from one of the targeted families emerge as a threat.
What viruses does ReVAMPP target?
What viruses does ReVAMPP target?
Research Center projects are focused on innovative multidisciplinary approaches to develop medical countermeasures to combat high-consequence viruses from 9 virus families: Flaviviridae, Paramyxoviridae, Picornaviridae, Togaviridae, Arenaviridae, Hantaviridae, Nairoviridae, Phenuiviridae, and Peribunyaviridae.
OUR INNOVATIVE APPROACH
Main Areas of Focus
ReVAMPP is a research network designed to conduct fundamental basic to IND-enabling translational research on representative viruses, or “prototype pathogens,” within specific virus families.
Why these families?
To focus resources and maximize time, NIH/NIAID created the ReVAMPP program with the goal of gathering extensive knowledge from select virus families of concern. NIAID prioritized virus families of concern with insufficient research, inadequate medical countermeasures, and low to moderate historical support.
Virus Families of Concern
Click on a virus family name for representative viruses being studied.
The ReVAMPP Network
Click on a ReVAMPP Center name for additional information.
PARTNERING FOR GLOBAL IMPACT
ReVAMPP BY THE NUMBERS
Preparing to Respond through Collaboration and
Knowledge Generation
CONNECT WITH ReVAMPP
Sign Up for Updates
Stay updated on our research efforts.
CONNECT WITH ReVAMPP
Join our LinkedIn Group
To stay connected and learn more about our preparedness work.